3.4.24.B10	0.0000167	-	N-[(2E)-3-(3-bromophenyl)-2-[(furan-2-ylcarbonyl)amino]prop-2-enoyl]glycine	IC50: 16.7 nM	667947	
3.4.24.B10	0.0000248	-	N-[(2E)-3-(4-bromofuran-2-yl)-2-[[(5-bromofuran-2-yl)carbonyl]amino]prop-2-enoyl]alanine	IC50: 24.8 nM	667947	
3.4.24.B10	0.000025	-	batimastat	with 5-Fam-HALAQA(homophenylalanine)RSK-NH2 as substrate, at pH 8.0 and 22°C	733079	
3.4.24.B10	0.000028	-	batimastat	with 5-Fam-FFLAQA(homophenylalanine)RSK-NH2 as substrate, at pH 8.0 and 22°C	733079	
3.4.24.B10	0.0000405	-	N-[(2E)-3-(2-fluorophenyl)-2-[(phenylcarbonyl)amino]prop-2-enoyl]valine	IC50: 40.5 nM	667947	
3.4.24.B10	0.0000423	-	N-[(2E)-3-furan-2-yl-2-[(furan-2-ylcarbonyl)amino]prop-2-enoyl]alanine	IC50: 42.3 nM	667947	
3.4.24.B10	0.00012	-	MMP inhibitor V	with 5-Fam-FFLAQA(homophenylalanine)RSK-NH2 as substrate, at pH 8.0 and 22°C	733079	
3.4.24.B10	0.00018	-	MMP inhibitor V	with 5-Fam-HALAQA(homophenylalanine)RSK-NH2 as substrate, at pH 8.0 and 22°C	733079	
3.4.24.B10	0.00035	-	TAPI-0	with 5-Fam-HALAQA(homophenylalanine)RSK-NH2 as substrate, at pH 8.0 and 22°C	733079	
3.4.24.B10	0.0004	-	TAPI-0	with 5-Fam-FFLAQA(homophenylalanine)RSK-NH2 as substrate, at pH 8.0 and 22°C	733079